|
|
|
|
||
What is the market telling us about HALO?Any thoughts? Trying to understand. Is it: 1. A buyout is imminent? 2. Nivolumab subcutaneous will be successful and all BMY milestones will be triggered? 3. IV conversion to subcutaneous for recent dara + breast cancer will be greater than 50% in Q3; 4. New partnership deals? 5. Accelerated approvals for phase 3 by FDA as too risky to have patients dosed IV for hours in a hospital which might need the bed and the nurse for COVID-19 emergencies 6. The $1B royalties annually will be reached much sooner 7. Halozyme about to buyout a disruptive technology which in combo with rHuPH20 will extend IP patent expiration (AWE technology by ATNM would be perfect fit) A combination of all of the above? What am I missing. We hit all time high once again. What's brewing? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
761 | Re: What is the market telling us about HALO? | ladcad | 2 | 7/6/2020 1:11:36 PM |